A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)

Tomoya Fukui, Nobuaki Mamesaya, Toshiaki Takahashi, Kazuma Kishi, Takahiro Yoshizawa, Takaaki Tokito, Koichi Azuma, Kei Morikawa, Satoshi Igawa, Yusuke Okuma, Yuta Yamanaka, Shinobu Hosokawa, Takashi Kasai, Ken Masubuchi, Shinji Nakamichi, Masaharu Aga, Jiichiro Sasaki, Akiko Kada, Akiko Saito, Katsuhiko Naoki, Hiroaki Okamoto